Drugs / MK-1088
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05394350 | Jul 2022 → Sep 2023 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05394350 ↗ |
| Route | Oral | “Participants received MK-1088 daily (QD) orally” NCT05394350 ↗ |